Evaluation of Antibiotic Absorption in Patients with Short Bowel Syndrome Undergoing Treatment for Bacterial Infection

The primary objective of this study is to evaluate the **absorption** of antibiotics with good oral bioavailability in patients with **short bowel syndrome** who are being treated for a bacterial infection. This is clinically relevant as short bowel syndrome can significantly impact the absorption of orally administered medications, potentially affecting their efficacy and safety. Understanding the absorption characteristics in this patient population is crucial for optimizing antibiotic therapy and ensuring effective treatment outcomes.

The clinical trial involves participants diagnosed with **short bowel syndrome** who are undergoing treatment with antibiotics for a bacterial infection. The study population includes both male and female subjects, with an age range spanning from adolescents to adults. The trial does not specifically target a vulnerable population. However, the sponsor has not provided information regarding the total number of participants involved in the study. The selection criteria for the trial population, as well as any lifestyle considerations such as diet or physical activity, have not been disclosed. Key inclusion or exclusion criteria are also not specified in the available data.

The clinical trial is designed to evaluate the absorption of antibiotics with good oral bioavailability in patients with **short bowel syndrome** who are being treated for a bacterial infection. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know which treatment the participants are receiving, thereby minimizing bias. The trial is set to commence recruitment on December 9, 2022, and is expected to conclude by June 9, 2026, providing a comprehensive duration for data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a thorough assessment of the participant's medical history and current health status. Following the inclusion visit, participants will attend regular follow-up visits, which are scheduled to monitor the efficacy and safety of the treatment, as well as to collect data on antibiotic absorption. These visits are crucial for ensuring participant safety and for gathering consistent data throughout the trial period. The study will culminate in an end-of-study visit, where final assessments will be conducted, and participants will be debriefed on the study's outcomes.

The expected length of participant involvement in the trial is determined by the study's timeline, with each participant's involvement lasting until the end-of-study visit unless specific conditions necessitate early termination. Such conditions may include adverse reactions to the treatment, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the integrity of the data collected and the safety of all participants involved.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, or frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these elements can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be elaborated upon in this context.

The clinical trial's efficacy assessment details are not explicitly provided in the available data. Information regarding the parameters or endpoints used to evaluate efficacy, such as symptom improvement scores, biomarker levels, or disease remission rates, is not specified. Additionally, the methods and schedule for measuring, collecting, and analyzing these efficacy parameters, including any tools or instruments involved, are not mentioned. The trial is categorized under phase 6, with an estimated recruitment start date of December 9, 2022, and an estimated end date of June 9, 2026. However, specific efficacy assessment details remain unspecified in the provided data.